Brainstorm Cell Therapeutics (NASDAQ: BCLI) A somewhat positive media coverage received, Accern Reports



Media stories about Brainstorm Cell Therapeutics (NASDAQ: BCLI) are somewhat similar to Saturday, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage in the press by monitoring more than 20 million news and blog sources. Accern ranks the coverage of public companies on a scale from negative one to positive, with scores that are closest to one being the most favorable. Brainstorm Cell Therapeutics earned a news sensitivity score of 0.24 on the Accern scale. Accern also gave media lists about the biotechnology company an impact score of 46.2481051300635 out of 100, indicating that the recent news coverage in the press will have little effect on the share price of the share over the next few days.

Here are some of the media stories that may have affected the analysis of Accern Sentiment:

BCLI has been the subject of a number of recent reports from analysts. Maxim Group set a target price of $ 9.00 on Brainstorm Cell Therapeutics shares and gave the company a "buy" score in a study letter on Monday, July 2. HC Wainwright repeated a "buy" rating and set a price target of $ 11.00 on Brainstorm Cell Therapeutics shares in a research report on Tuesday, June 26. Finally, ValuEngine has upgraded Brainstorm Cell Therapeutics shares from a & # 39; hold & # 39; credit to a & # 39; buy & # 39; rating in a research report on Wednesday, May 16.

NASDAQ: BCLI swapped $ 0.14 during trading hours on Friday and reached $ 3.95. 106,933 shares of the company's shares were exchanged, compared to the average volume of 55,975. The stock has a market capitalization of $ 83.50 million, a price-earnings ratio of -15.19 and a beta of 2.06. Brainstorm Cell Therapeutics has a 12 month low of $ 2.88 and a 12 month peak of $ 5.35.

Brainstorm Cell Therapeutics (NASDAQ: BCLI) has published its quarterly results for the last time on Monday, July 23rd. The biotechnology company reported ($ 0.16) earnings per share for the quarter, while the consensus estimates of the analysts ($ 0.14) did not appear ($ 0.02). Research analysts predict that Brainstorm Cell Therapeutics will be -0.49 per share for the current fiscal year.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, is engaged in the development and commercialization of adult stem cell therapies for the central nervous system (CNS), designed to meet the unmet medical needs of patients with debilitating neurodegenerative diseases. The company owns rights to develop and market its NurOwn technology that uses the patient's own cells, which have been developed outside the body, to produce and excrete factors known to be the survival of promote neurons.

Read more: Relative strength index

Insider buying and selling quarterly for Brainstorm Cell Therapeutics (NASDAQ: BCLI)

Receive news and ratings for Brainstorm Cell Therapeutics Daily – Enter your email address below to receive a concise, daily summary of the latest news and ratings from analysts for Brainstorm Cell Therapeutics and related companies with the FREE daily email newsletter from MarketBeat.com.


Source link

Leave a Reply